TimesSquare Capital Management LLC Sells 57,863 Shares of Stevanato Group S.p.A. $STVN

TimesSquare Capital Management LLC reduced its position in Stevanato Group S.p.A. (NYSE:STVN) by 1.7% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 3,267,676 shares of the company’s stock after selling 57,863 shares during the period. Stevanato Group accounts for approximately 1.2% of TimesSquare Capital Management LLC’s portfolio, making the stock its 25th largest holding. TimesSquare Capital Management LLC’s holdings in Stevanato Group were worth $84,143,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Pembroke Management LTD raised its holdings in Stevanato Group by 11.9% during the 3rd quarter. Pembroke Management LTD now owns 1,283,216 shares of the company’s stock valued at $33,043,000 after acquiring an additional 136,710 shares during the period. Cooper Investors PTY Ltd. raised its stake in shares of Stevanato Group by 251.7% during the 3rd quarter. Cooper Investors PTY Ltd. now owns 590,308 shares of the company’s stock valued at $15,200,000 after purchasing an additional 422,478 shares during the period. Thrivent Financial for Lutherans raised its stake in shares of Stevanato Group by 7.1% during the 3rd quarter. Thrivent Financial for Lutherans now owns 2,372,390 shares of the company’s stock valued at $61,089,000 after purchasing an additional 156,733 shares during the period. Mutual of America Capital Management LLC lifted its holdings in Stevanato Group by 6.5% during the 2nd quarter. Mutual of America Capital Management LLC now owns 707,123 shares of the company’s stock worth $17,275,000 after purchasing an additional 43,389 shares in the last quarter. Finally, Ranger Investment Management L.P. boosted its stake in Stevanato Group by 125.6% in the 2nd quarter. Ranger Investment Management L.P. now owns 1,321,030 shares of the company’s stock worth $32,273,000 after purchasing an additional 735,417 shares during the period.

Analyst Ratings Changes

STVN has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of Stevanato Group in a report on Monday, December 29th. Wall Street Zen lowered shares of Stevanato Group from a “buy” rating to a “hold” rating in a report on Saturday. Jefferies Financial Group set a $17.50 target price on shares of Stevanato Group in a research note on Tuesday. Finally, Morgan Stanley started coverage on shares of Stevanato Group in a research report on Monday, December 1st. They set an “equal weight” rating and a $24.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Stevanato Group has a consensus rating of “Moderate Buy”.

Stevanato Group Trading Up 3.2%

Shares of STVN opened at €16.10 on Friday. Stevanato Group S.p.A. has a 1-year low of €13.91 and a 1-year high of €28.00. The company has a market capitalization of $4.88 billion, a P/E ratio of 28.25, a P/E/G ratio of 1.32 and a beta of 0.58. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.89 and a quick ratio of 1.30. The firm’s 50 day simple moving average is €19.13 and its 200 day simple moving average is €22.45.

Stevanato Group Company Profile

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.